MA43745A - Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer - Google Patents
Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancerInfo
- Publication number
- MA43745A MA43745A MA043745A MA43745A MA43745A MA 43745 A MA43745 A MA 43745A MA 043745 A MA043745 A MA 043745A MA 43745 A MA43745 A MA 43745A MA 43745 A MA43745 A MA 43745A
- Authority
- MA
- Morocco
- Prior art keywords
- dihydropyrrolo
- pyrazole
- cancer
- treatment
- carbonitrile derivatives
- Prior art date
Links
- SMJKYKNYWBAFPU-UHFFFAOYSA-N 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carbonitrile Chemical class N1N=CC2=C1CN(C2)C#N SMJKYKNYWBAFPU-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1604638.5A GB201604638D0 (en) | 2016-03-18 | 2016-03-18 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43745A true MA43745A (fr) | 2018-11-28 |
Family
ID=55968542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043745A MA43745A (fr) | 2016-03-18 | 2017-03-17 | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11306096B2 (enExample) |
| EP (1) | EP3430012B1 (enExample) |
| JP (1) | JP6959248B2 (enExample) |
| CN (1) | CN108473502B (enExample) |
| GB (1) | GB201604638D0 (enExample) |
| MA (1) | MA43745A (enExample) |
| WO (1) | WO2017158381A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277677B9 (en) | 2015-03-30 | 2021-07-14 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| WO2017087885A1 (en) | 2015-11-19 | 2017-05-26 | Dana-Farber Cancer Institute, Inc. | Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| US11059809B2 (en) | 2017-06-20 | 2021-07-13 | Mission Therapeutics Limited | Substituted cyanopyrrolidines with activity as DUB inhibitors |
| US11247987B2 (en) | 2017-10-06 | 2022-02-15 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| EP3746124A4 (en) | 2018-01-30 | 2021-10-27 | Foghorn Therapeutics Inc. | COMPOUNDS AND THEIR USES |
| DK3784661T3 (da) | 2018-04-25 | 2024-02-12 | Bayer Ag | Hidtil ukendte heteroaryl-triazol- og heteroaryl-tetrazol-forbindelser som pesticider |
| IL278291B2 (en) | 2018-05-17 | 2023-10-01 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| LT3860989T (lt) | 2018-10-05 | 2023-06-12 | Forma Therapeutics, Inc. | Sulieti pirolinai, kurie veikia kaip ubikvitinui specifinės proteazės 30 (ups30) inhibitoriai |
| US12473334B2 (en) | 2018-10-17 | 2025-11-18 | Dana-Farber Cancer Institute, Inc. | SWI/SNF family chromatin remodeling complexes and uses thereof |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| EP3917529A4 (en) | 2019-01-29 | 2022-11-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB201905371D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| PH12022551937A1 (en) | 2020-01-29 | 2023-10-23 | Foghorn Therapeutics Inc | Compounds and uses thereof |
| JP2023512038A (ja) * | 2020-01-29 | 2023-03-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| CN115461340A (zh) | 2020-04-08 | 2022-12-09 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| WO2021239863A1 (en) | 2020-05-28 | 2021-12-02 | Mission Therapeutics Limited | N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction |
| CN115698001A (zh) | 2020-06-04 | 2023-02-03 | 特殊治疗有限公司 | 具有作为usp30抑制剂活性的n-氰基吡咯烷类化合物 |
| FI4161929T3 (fi) | 2020-06-08 | 2025-07-30 | Mission Therapeutics Ltd | 1-(5-(2-syaanipyridin-4-yyli)oksatsoli-2-karbonyyli)-4-metyyliheksahydropyrrolo[3,4-b]pyrroli-5(1h)-karbonitriili usp30-inhibiittorina käytettäväksi mitokondrioiden toimintahäiriön, syövän ja fibroosin hoitamisessa |
| GB202016800D0 (en) | 2020-10-22 | 2020-12-09 | Mission Therapeutics Ltd | Novel compounds |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| US20250034122A1 (en) | 2021-12-01 | 2025-01-30 | Mission Therapeutics Limited | Substituted n-cyanopyrrolidines with activity as usp30 inhibitors |
| GB202200753D0 (en) | 2022-01-21 | 2022-03-09 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001256981A1 (en) | 2000-04-06 | 2001-10-23 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| US20130156731A1 (en) | 2009-12-22 | 2013-06-20 | Kevin X. Chen | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas |
| AU2011305315A1 (en) * | 2010-09-24 | 2013-03-28 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| WO2012174199A1 (en) | 2011-06-16 | 2012-12-20 | Merck Sharp & Dohme Corp. | Imidazopyridin-2-one derivatives |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| US9487545B2 (en) | 2011-09-30 | 2016-11-08 | Xuanzhu Pharma Co., Ltd. | Fused ring-containing oxazolidinones antibiotics |
| JP2016504365A (ja) * | 2012-12-28 | 2016-02-12 | アメリカ合衆国 | Ｕｓｐ１／ｕａｆ１デユビキチナーゼ複合体阻害剤及びその使用 |
| WO2015154038A1 (en) | 2014-04-04 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN111393434B (zh) | 2014-04-30 | 2022-11-04 | 哥伦比亚大学董事会 | 取代的4-苯基哌啶及其制备和用途 |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| EP3277677B9 (en) | 2015-03-30 | 2021-07-14 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| EP3322702B1 (en) | 2015-07-14 | 2019-11-20 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| WO2017163078A1 (en) | 2016-03-24 | 2017-09-28 | Mission Therapeutics Limited | 1-cyano-pyrrolidine derivatives as dbu inhibitors |
| EP3519385B1 (en) | 2016-09-27 | 2020-11-18 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of usp30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
-
2016
- 2016-03-18 GB GBGB1604638.5A patent/GB201604638D0/en not_active Ceased
-
2017
- 2017-03-17 WO PCT/GB2017/050755 patent/WO2017158381A1/en not_active Ceased
- 2017-03-17 JP JP2018548677A patent/JP6959248B2/ja active Active
- 2017-03-17 CN CN201780007893.4A patent/CN108473502B/zh active Active
- 2017-03-17 MA MA043745A patent/MA43745A/fr unknown
- 2017-03-17 EP EP17713402.0A patent/EP3430012B1/en active Active
- 2017-03-17 US US16/080,229 patent/US11306096B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| GB201604638D0 (en) | 2016-05-04 |
| WO2017158381A8 (en) | 2018-01-11 |
| US20210221813A1 (en) | 2021-07-22 |
| US11306096B2 (en) | 2022-04-19 |
| CN108473502B (zh) | 2022-04-26 |
| JP6959248B2 (ja) | 2021-11-02 |
| EP3430012A1 (en) | 2019-01-23 |
| WO2017158381A1 (en) | 2017-09-21 |
| JP2019508462A (ja) | 2019-03-28 |
| EP3430012B1 (en) | 2021-06-16 |
| CN108473502A (zh) | 2018-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43745A (fr) | Dérivés de 4,6-dihydropyrrolo[3,4-c]pyrazole-5(1h)-carbonitrile pour le traitement du cancer | |
| MA45146A (fr) | Dérivés de pyrazolopyridine pour le traitement du cancer | |
| MA43746A (fr) | Dérivés de 2-cyanoisoindoline pour le traitement du cancer | |
| EP3781564C0 (en) | PYRIDAZINE DERIVATIVES FOR TREATING CANCER | |
| IL268737A (en) | Processes for the preparation of benzodiapine derivatives | |
| MA52987A (fr) | Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak | |
| ZA202103099B (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| HUE053643T2 (hu) | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése | |
| MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
| IL287168A (en) | Kit of pyrrolotriazine derivatives for the treatment of diseases mediated by pdgfra | |
| ZA201807810B (en) | Adenosine derivatives for use in the treatment of cancer | |
| EP3380475A4 (en) | OCTAHYDROPYRROLO [3,4-C | |
| EP3436014A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA | |
| EP3454896A4 (en) | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV | |
| SI3353177T1 (sl) | Triciklični heterocikli za zdravljenje raka | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| EP3423048A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER | |
| EP3709968C0 (de) | Emulsionen zur behandlung von schleimhautinfektionen | |
| EP3346989A4 (en) | STABLE LIPOSOMAL FORMULATIONS OF RAPAMYCIN AND RAPAMYCIN DERIVATIVES FOR THE TREATMENT OF CANCER | |
| MA42988A (fr) | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide | |
| MX2017009597A (es) | Derivados de imidazo[2,1-b]tiazol y 5,6-dihidroimidazo[2,1-b]tiazo l utiles como inhibidores de s100. | |
| PT3277687T (pt) | Derivados de 7-(morfolin-4-il)pirazole[1,5-a]pirimidina que são úteis para o tratamento de doenças imunitárias ou inflamatórias ou cancro | |
| MA54223A (fr) | Dérivés de 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one servant d'inhibiteurs de hpk1 pour le traitement du cancer | |
| HK40061811B (zh) | 用於制备三环pi3k抑制剂化合物的方法及用其治疗癌症的方法 | |
| IL253427A0 (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose |